Lupin Awaits 'Clarity' On Albuterol Filing
Says Other US Launches On Track Despite Deferred FDA Inspections
Executive Summary
After lower growth in its India business and impaired operations at five manufacturing units hit by US FDA action impacted Lupin's third-quarter revenues, one-offs sent its net profit crashing. While deferring reinspection timelines for its Goa and Somerset plants, the company remains confident of adding at least 15 products to its US portfolio in FY21.
You may also be interested in...
Perrigo Rolls Out US ProAir Rival
Perrigo has received US FDA approval for a generic version of Teva’s ProAir albuterol inhaler. The firm is immediately launching a “limited quantity” but is also ramping up production with partner Catalent to meet future demand.
Cipla To Recalibrate US Investments
Cipla is to moderate investments across its US generics R&D and specialty business, while its India business components – prescription, trade generic and consumer health – are being brought under a “single capital allocation framework.”
Cipla To Recalibrate US Investments, Partnering Plan For Specialty Business
Cipla to moderate investments across US generics R&D and specialty business, while its India business components - prescription, trade generic and consumer health - are being brought under a “single capital allocation framework.”